Original Bai Yu Mine.com
wonderful content
On October 20, the official website of CDE showed that Jiangsu Enhua Pharmaceutical's lacosamide injection was accepted for imitation of 4 types of production reports. m Inner Network data shows that lacosamide's global sales exceeded US$1.5 billion in 2021. Although China's public medical terminals are less than 100 million yuan, their potential is amazing. increased by more than 400% year-on-year, and continued to rise by 204.80% in the first half of 2022, ranking 9th among the common names of anti-epileptic drugs.
As one of the anti-epileptic drugs, lacosamide has little side effects and does not undergo liver metabolism. It will not have clinically significant drug interactions with other anti-epileptic drugs. Due to its unique mechanism of action, it can be used as a new treatment option for some patients with epilepsy seizures .
m Inside Network data shows that lacosamide's global sales exceeded US$1.5 billion in 2021. Although the terminal sales of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as Chinese public medical institutions) are less than 100 million yuan, their potential is amazing, with a year-on-year increase of more than 400%. It continued to rise by 204.80% in the first half of 2022, ranking 9th among the common names of anti-epileptic drugs.
0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 Three companies have production approval documents for Racosamide injection. Jiangxi Qingfeng Pharmaceutical and Shi Pharmaceutical Group Ouyi Pharmaceutical have both been approved in the new category as deemed to be passed. At present, 8 companies including Jiangsu Coast Pharmaceutical | Yangtze River Pharmaceutical Group , Shijiazhuang Four Pharmaceuticals , and Hefei Yifan Biopharmaceutical are under review.
Since the beginning of this year, Enhua Pharmaceutical has two products under review. Among them, no company has approved the Oselidine fumarate injection and is expected to win the first in China.
Source: Minnei.com database, CDE official website, etc.
Note: Minnei.com "Terminal Competition Pattern of Public Medical Institutions in China", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, and village clinics. ; the above sales are calculated based on the average retail price of the product at the terminal.
